AI-extracted from the 10-Q filed 2026-08-10 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue grew 38% YoY to $753.2M in Q2, driven by Rest of World expansion and US weight loss momentum, but net loss of $86.3M reflects $62.5M legal accrual and 112% cost-of-revenue growth.
Biggest Revenue Drivers
United States Revenue$621.8M+16% YoY
Increased from growth in Hers brand weight loss offerings, partially offset by shift to shorter shipping cadences reducing revenue recognition timing.
Rest of World Revenue$131.4M+1,641% YoY
Primary driver from Eucalyptus acquisition closing in June 2026, providing operations in Australia, UK, Germany, Ireland, Canada, and Japan.
Biggest Revenue Drivers
Total revenue: $753.2M+38% YoY
United States Revenue$621.8M+16% YoY
Increased from growth in Hers brand weight loss offerings, partially offset by shift to shorter shipping cadences reducing revenue recognition timing.
Rest of World Revenue$131.4M+1,641% YoY
Primary driver from Eucalyptus acquisition closing in June 2026, providing operations in Australia, UK, Germany, Ireland, Canada, and Japan.
Largest Expense Items
Cost of revenue$272.4M+112% YoY
Increased product, packaging, and shipping costs driven by weight loss offerings and $28.5M inventory write-downs from US weight loss strategic shift.
General and administrative$165.4M+146% YoY
Included $47.5M legal contingency accrual for FTC matter; also higher employee compensation (+$24.0M), depreciation (+$10.7M), and acquisition costs.
Marketing$262.2M+20% YoY
Customer acquisition costs increased to $229.5M (+$41.1M) from expanded search and affiliate marketing investment.
Operations and support$95.5M+44% YoY
Driven by employee compensation (+$8.9M), fulfillment/transaction costs (+$8.3M), and depreciation (+$5.7M) from increased scale.
Margins: Gross margin declined to 64% from 76% YoY, primarily due to weight loss offerings with shorter shipping cadences, higher fulfillment costs, international acquisition integration, and $28.5M restructuring inventory charges related to the March 2026 US weight loss strategic shift away from compounded GLP-1s.
Watch Items from the Filing
FTC legal contingency: $62.5M accrual recorded for ongoing FTC action (filed July 29, 2026) alleging unfair practices; outcome uncertain and amount may change materially as litigation progresses.
Regulatory uncertainty on compounded GLP-1s: FDA statement in February 2026 indicated intent to restrict GLP-1 ingredients in mass-marketed compounded drugs; HHS referred company to DOJ for investigation; company pivoted in March 2026 to branded products only.
Eucalyptus acquisition deferred consideration: $683.9M payable in six quarterly installments; company has option to settle majority of this and earn-outs ($96.6M maximum) via stock, capped at 19.9% of Class A shares outstanding.
Receivables surge: Manufacturer discount and rebate receivables jumped to $347.4M as of June 30, 2026 from immaterial balance at December 31, 2025, reflecting significant inventory positioning for weight loss and other offerings.
Working capital deficit of $98.6M as of June 30, 2026 versus $363.2M surplus at December 31, 2025, driven by Eucalyptus deferred acquisition payable; company retains $162.4M availability under $175M revolving credit facility.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
About Hims & Hers Health, Inc. (HIMS): stock profile, AI score and financials
Hims & Hers Health, Inc. (HIMS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HIMS at 53.4/100 on a composite quality score built from its SEC filings, placing it at rank #1,396 of 2,925 stocks — the top half of the AI-ranked universe. HIMS scores in the top quartile across revenue growth (94.9), earnings quality (81.6). Areas of concern include profitability (21.1) and balance sheet strength (22.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Hims & Hers Health, Inc. reports quarterly revenue of $753.2M, net income of $-86.3M, an operating margin of -12.9%. Top institutional holders of HIMS by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. HIMS trades on the NYSE exchange and files with the SEC under CIK 1773751. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HIMS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Hims & Hers Health, Inc. directly from SEC EDGAR.